Allergan Aesthetics, an AbbVie company, announced that it will present new data from its facial aesthetics portfolio at the 2026 International Master Course on Aging Science (IMCAS) World Congress, scheduled for January 29-31, 2026, in Paris, France. The presentations will include nine e-posters covering products such as the first-in-class botulinum neurotoxin serotype E (TrenibotulinumtoxinE, "TrenibotE"), onabotulinumtoxinA, hyaluronic acid-based fillers, and an innovative filler with biostimulatory properties. Pooled Phase 3 data on TrenibotulinumtoxinE for glabellar lines and Phase 4 studies of onabotulinumtoxinA for upper facial lines will be featured, focusing on efficacy, safety, and patient satisfaction. These results will be unveiled during the congress and have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CG72380) on January 28, 2026, and is solely responsible for the information contained therein.